Bon Secours Mercy Health moves deeper into outpatient surgery with $5.7 billion Surgery Partners deal
Bon Secours Mercy Health is taking a controlling stake in Surgery Partners in a take-private transaction that values the short-stay surgical platform at $5.7 billion. The agreement places one of the largest Catholic nonprofit health systems squarely inside a business model that has become increasingly central to U.S. care delivery: outpatient procedures performed in ambulatory surgery centers and surgical hospitals rather than traditional inpatient settings.
The deal is expected to close in the first quarter of next year, pending approvals. If completed as structured, the combined footprint would include more than 200 locations and create one of the country’s largest outpatient surgical care platforms. For a system with nearly 60,000 employees and 47 hospitals, the move is not just a financial transaction. It is a direct bet that a larger share of routine and elective surgery will continue migrating away from the acute-care hospital.
A single sentence captures the strategic logic: surgical volume is moving to lower-cost settings, and systems are racing to own those settings.
A platform built for short-stay care
Surgery Partners operates ambulatory surgery centers, surgical hospitals, and a network of about 5,000 affiliated physicians across 30 states. Its 2025 revenue reached $3.31 billion, with adjusted earnings per share of $0.47. Those figures matter because they show a business that already functions at national scale, with enough operational density to make integration attractive for a large health system seeking breadth rather than a single-market footprint.
The terms call for Bon Secours’ HealthSpan Partners affiliate to buy the remaining shares with cash at $23.50 per share, while Bain Capital Private Equity retains and rolls over its roughly 39% stake. Bain had previously offered in January 2025 to acquire the shares it did not already own at $25.75 apiece, implying a roughly $6.7 billion enterprise valuation. That bid was rejected a few months later, setting the stage for the new structure.
The transaction reflects a familiar pattern in provider consolidation: private equity helps scale the platform, then a health system steps in when outpatient assets become strategically more valuable as a long-term care delivery channel than as a stand-alone financial asset.
Why health systems want ambulatory capacity
Bon Secours’ leadership framed the deal as an extension of its mission to serve more people in more communities and across a broader range of care settings. Wael Haidar, M.D., president of clinical operations, described the arrangement as a way to expand access to high-quality outpatient care while supporting physicians and helping patients receive the right care in the right setting.
The clinical logic is straightforward. Many procedures do not require a hospital bed, and patients increasingly expect care that is less disruptive, less expensive, and easier to schedule. As payers and policymakers continue pushing appropriate procedures outside the hospital, systems with a robust ambulatory footprint gain leverage over where volume lands, how efficiently procedures are performed, and how physicians are aligned across sites of care.
The policy backdrop matters here. The slow wind-down of Medicare’s inpatient-only list has been one of the forces nudging care toward outpatient venues. When procedures no longer require an inpatient designation, the economic center of gravity shifts with them. Hospitals that own ambulatory assets can keep cases within their orbit instead of watching them migrate to independent operators.
Bon Secours brings hospital scale and capital discipline
Bon Secours Mercy Health reported just under $14 billion in total operating revenue through 2025, along with $324 million in recurring operating income and a 2.3% recurring operating margin. It also reported a $1.1 billion bottom line. Those numbers suggest a large system with enough financial capacity to support a transaction of this size, even as the deal will be financed through a combination of cash on hand and newly secured debt.
The system’s existing portfolio includes a 41% stake in Ensemble Health Partners, the revenue cycle management company that recently drew a new private equity investor in a strategic recapitalization. That history signals a leadership team comfortable with adjacent businesses that sit just outside the hospital walls but remain tightly linked to clinical throughput, reimbursement, and site-of-care strategy.
Bon Secours has not framed the acquisition as a national expansion for expansion’s sake. The plan is to keep Surgery Partners’ operations, brand, and headquarters in place while preserving it as a secular organization. In practical terms, that suggests continuity in day-to-day management while allowing the nonprofit system to capture the scale benefits of ownership.
A growing model among major Catholic systems
The clearest comparison is Ascension’s $3.9 billion purchase of AMSURG, which closed over the summer after regulatory clearance. That deal, like this one, illustrates how major nonprofit systems are treating ambulatory surgery as a strategic growth lane rather than a peripheral outpatient service.
In both cases, the target brings a broad national network, physician relationships, and an established short-stay platform. For large systems, the appeal is not limited to revenue. Ownership of ambulatory sites can help steer cases away from crowded inpatient campuses, create more predictable surgical flow, and concentrate high-acuity hospital capacity where it is truly needed.
Eric Evans, chief executive of Surgery Partners, called the transaction the best path forward for the company, citing an all-cash premium for shareholders and lasting benefits for patients, physicians, and other stakeholders. That language fits the economics of a take-private deal, but it also reflects a broader operating reality: outpatient surgery has become a core battleground in provider competition.
What the deal changes for patients and physicians
If the transaction closes as planned, the most immediate changes will likely be structural rather than visible at the bedside. Patients should still encounter the same brand, the same headquarters, and in many cases the same local sites. The larger difference lies behind the scenes: capital, contracting power, referral pathways, and the ability to coordinate surgical care across a much broader footprint.
Physicians may see expanded access to ambulatory facilities and more opportunities to practice in settings designed around efficient elective surgery. For hospitals, the deal could help reserve inpatient resources for higher-acuity cases while keeping profitable and operationally predictable procedures within the system’s own network.
The unresolved issues are regulatory rather than clinical. Antitrust review, financing execution, and the integration of a public surgical company into a nonprofit system will determine how much of the promised scale is actually realized. The purchase price is set; the operational outcome is not.